What is the difference between BAM15 and GW-0742?

BAM15: BAM15 is a synthetic small-molecule mitochondrial uncoupler (protonophore) — not a peptide — studied preclinically for obesity and metabolic disease as a potentially safer alternative to DNP. It has n... GW-0742: GW-0742 is a synthetic small-molecule PPARδ (PPAR-beta/delta) agonist developed by GlaxoSmithKline as a phenoxyacetic-acid/thiazole derivative—not a peptide or hormone. It exhibits ~1000-fold selectiv...

What does the research say about BAM15 vs GW-0742?

BAM15: In diet-induced obese mice, BAM15 reduced fat mass and improved insulin sensitivity without changing food intake or lean mass (Nature Communications 2020); other mouse work shows benefit in diabetes, and in sepsis/acute kidney injury. Rodent PK is ~67% oral bioavailability with a ~1.7 h half-life; there is no human PK, safety, or dosing data. Not a… GW-0742: No human efficacy or safety data exist; the only identified human exposure is a single 15 mg oral dose administered to volunteers solely to characterize urinary metabolites for an anti-doping detection assay—a bioanalytical study yielding no therapeutic or safety information. Preclinical rodent findings include: oral GW-0742 (30 mg/kg/day × 3 weeks…

BAM15 vs GW-0742

Q: Can you stack BAM15 and GW-0742?

BAM15 (metabolic) and GW-0742 (metabolic) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of BAM15 and GW-0742 — mechanism, side effects, legal status, and pricing.

BAM15

BAM15 is a synthetic small-molecule mitochondrial uncoupler (protonophore) — not a peptide — studied preclinically for obesity and metabolic disease as a potentially safer alternative to DNP. It has never been tested in humans, has no regulatory approval, and was added to the WADA Prohibited List as an AMPK activator. It is sold as a gray-market research chemical.

Profile Prices Testing

GW-0742

GW-0742 is a synthetic small-molecule PPARδ (PPAR-beta/delta) agonist developed by GlaxoSmithKline as a phenoxyacetic-acid/thiazole derivative—not a peptide or hormone. It exhibits ~1000-fold selectivity for human PPARδ (EC50 = 1.1 nM) over PPARα and PPARγ. Never advanced past preclinical development, GW-0742 has no approved human therapeutic use and no registered clinical trials. It is prohibited at all times under WADA as a member of the banned PPARδ-agonist class (Hormone and Metabolic Modulators), though not individually named on the list.

Profile Prices Testing

BAM15

GW-0742

Category

Metabolic

Legal Status

Research Only

Mechanism

BAM15 increases proton permeability of the inner mitochondrial membrane, letting protons leak back into the matrix independent of ATP synthase — dissipating the proton-motive force and uncoupling electron transport from ATP synthesis, which raises substrate oxidation and heat production. Unlike DNP/FCCP it does not depolarize the plasma membrane at fully-uncoupling doses and is less cytotoxic than FCCP; downstream it activates AMPK (Kenwood et al., 2014). All data are cell/animal.

GW-0742 is a high-affinity, highly selective agonist of human PPARδ (EC50 = 1.1 nM for hPPARδ transactivation vs ~1.1 µM for hPPARα and ~2 µM for hPPARγ), conferring ~1000-fold selectivity for PPARδ over the other PPAR subtypes. Upon activation, PPARδ heterodimerizes with RXR and binds PPAR-response elements (PPREs) to alter transcription of genes governing fatty-acid oxidation, glucose utilization, and inflammatory signaling. In mice, however, GW-0742-induced hepatomegaly, hepatic/skeletal-muscle peroxisome proliferation, and skeletal myopathy were shown to be predominantly mediated by off-target PPARα cross-activation rather than PPARδ—a mechanism-based toxicity concern at animal-study exposures.

Side Effects

No human safety data — BAM15 has never been tested in humans
Class risk of mitochondrial uncouplers (as with DNP): dangerous hyperthermia and metabolic disruption at excess doses

Where Researchers Are Buying

Live · updated daily

COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower

BAM15

Best $/mg

$0.020/mg

Kimera ChemsC

1 trusted vendor listing

Compare all 1 vendor

GW-0742

Best $/mg

$0.058/mg

Kimera ChemsC

1 trusted vendor listing

Compare all 1 vendor

Lab Verification

COA corpus from Disclosed Labs — independently tested batches only.

BAM15

COAs

99.1%

Avg purity

Labs

Full testing data

GW-0742

COAs

99.6%

Avg purity

Labs

Full testing data

BAM15 Research Summary

In diet-induced obese mice, BAM15 reduced fat mass and improved insulin sensitivity without changing food intake or lean mass (Nature Communications 2020); other mouse work shows benefit in diabetes, and in sepsis/acute kidney injury. Rodent PK is ~67% oral bioavailability with a ~1.7 h half-life; there is no human PK, safety, or dosing data. Not approved; not a peptide.

Key references

GW-0742 Research Summary

No human efficacy or safety data exist; the only identified human exposure is a single 15 mg oral dose administered to volunteers solely to characterize urinary metabolites for an anti-doping detection assay—a bioanalytical study yielding no therapeutic or safety information. Preclinical rodent findings include: oral GW-0742 (30 mg/kg/day × 3 weeks) reduced right ventricular hypertrophy and systolic pressure in rats with chronic hypoxia-induced pulmonary hypertension but did not prevent pulmonary vascular remodeling; intraperitoneal GW-0742 (0.1 mg/kg) improved survival and reduced intestinal injury, leukocyte activation, cytokines, and apoptosis markers in a mouse gut ischemia/reperfusion model; and GW-0742 ameliorated hepatic steatosis, ER stress, and lung inflammation in various mouse models. Critically, mouse studies also demonstrated hepatomegaly, hepatic/skeletal-muscle peroxisome proliferation, and skeletal myopathy driven predominantly by off-target PPARα cross-activation, indicating mechanism-based toxicity risk.

Key references

Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ) — synthesis and biological activity (2003)

Can you stack BAM15 and GW-0742?

BAM15 and GW-0742 are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

BAM15 vs MOTS-c GW-0742 vs MOTS-c AOD-9604 vs BAM15 AOD-9604 vs GW-0742 5-Amino-1MQ vs BAM15 5-Amino-1MQ vs GW-0742 BAM15 vs NAD+GW-0742 vs NAD+

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.